Related Experiment Video
Updated: Aug 8, 2026
07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
Orlistat inhibits dietary cholesterol absorption
B Mittendorfer1, R E Ostlund, B W Patterson
1Department of Internal Medicine and Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Obesity Research
|October 12, 2001
Summary
Orlistat medication significantly reduces dietary cholesterol absorption in obese individuals. This mechanism may independently improve cholesterol levels and lipoprotein metabolism beyond weight loss effects.
Area of Science:
- Metabolic research
- Pharmacology
- Obesity studies
Background:
- Orlistat inhibits intestinal lipases, reducing dietary triglyceride absorption.
- Orlistat therapy is linked to greater reductions in low-density lipoprotein-cholesterol (LDL-C) than expected from weight loss alone.
Purpose of the Study:
- To investigate the effect of orlistat on dietary cholesterol absorption.
- To determine if reduced cholesterol absorption is a mechanism for orlistat's independent effect on plasma cholesterol concentration.
Main Methods:
- A standardized meal with dual cholesterol tracers (oral and intravenous) was used to measure cholesterol absorption.
- Eighteen subjects with class II abdominal obesity participated in a crossover study assessing orlistat's effect on cholesterol absorption.
Main Results:
- Orlistat treatment resulted in a 25% reduction in dietary cholesterol absorption (from 59% to 44%, p < 0.01).
- The tracer method for determining cholesterol absorption demonstrated good reproducibility.
Conclusions:
- Orlistat effectively inhibits dietary cholesterol absorption in obese subjects.
- This inhibition may contribute to beneficial effects on lipoprotein metabolism independent of weight reduction.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:18Lipids: Dietary Sources and Requirements
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...